Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
最新の財務諸表(Form-10K)によると、ABIVAX Société Anonymeの総資産は$0で、純損失は$0です。
ABVXの主要な財務比率は何ですか?
ABIVAX Société Anonymeの流動比率は0、純利益率は0、1株当たり売上高は$0です。
ABIVAX Société Anonymeの収益はセグメントまたは地域別にどのように分けられていますか?
ABIVAX Société Anonyme の最大収益セグメントは Banking and Related Activities で、最新の利益発表における収益は 293,750,000 です。地域別に見ると、United States が ABIVAX Société Anonyme の主要市場であり、収益は 293,750,000 です。